Darryl T. Martin, PhD
Assistant ProfessorDownloadHi-Res Photo
Cards
Appointments
Urology
Primary
Contact Info
About
Titles
Assistant Professor
Biography
Dr. Martin is a translational research scientist in the Department of Urology. He received his PhD from Memorial University of Newfoundland, Canada under the supervision of Drs. Robert Gendron and Hélène Paradis. Dr. Martin trained as a cancer molecular biologist using translational research models to study tumor growth and differentiation.
Dr. Martin is a member of the American Association for Cancer Research (AACR), the Society for Basic Urologic Research (SBUR) and the American Society for Biochemistry and Molecular Biology (ASBMB).
Appointments
Urology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- Memorial University of Newfoundland, BioMedical Sciences (2010)
Research
Overview
- Project 1 attempts to understand the mechanism(s) involved in chemotherapeutic resistant bladder tumors
- Project 2 aims to identify the molecular signatures of heterogeneous prostate cancers
- Project 3 uses functionalized nanoparticles to locate and treat prostate cancer
Resistant bladder tumors; Heterogeneous prostate cancers; Tumor-homing nanoparticles
Medical Subject Headings (MeSH)
Biomedical Research; Cystitis, Interstitial; Drug Delivery Systems; Inflammation; Nanomedicine; Prostatic Neoplasms; Translational Research, Biomedical; Tumor Microenvironment; Urinary Bladder Neoplasms
Research at a Glance
Yale Co-Authors
Frequent collaborators of Darryl T. Martin's published research.
Publications Timeline
A big-picture view of Darryl T. Martin's research output by year.
Research Interests
Research topics Darryl T. Martin is interested in exploring.
Robert M. Weiss, MD, FACS, FAAP
Michael S. Leapman, MD, MHS
Preston C. Sprenkle, MD
Angelique W. Levi, MD
Kamyar Ghabili Amirkhiz, MD
John Onofrey, PhD
23Publications
238Citations
Prostatic Neoplasms
Urinary Bladder Neoplasms
Drug Delivery Systems
Publications
2024
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchAltmetricConceptsDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage data
2023
PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING
Esmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Journal Of Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.Peer-Reviewed Original Research
2022
Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.
Choksi AU, Khan AI, Lokeshwar SD, Segal D, Weiss RM, Martin DT. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy. American Journal Of Clinical And Experimental Urology 2022, 10: 142-153. PMID: 35874285, PMCID: PMC9301064.Peer-Reviewed Original ResearchCitationsConceptsSurface of nanoparticlesNanoparticle-based therapiesCancer imagingAdministration of nanoparticlesFunctionalized nanoparticlesTherapeutic payloadsActive targetingNanoparticlesProstate cancer imagingRetention effectEnhanced permeabilityUnique advantagesC chemokine receptor type 4Chemokine receptor type 4Specific membrane antigenMolecular targetsCancer cellsProstate-specific membrane antigenReceptor type 4Knowledge of biomarkersRelated blood vesselsProstate cancer cellsExciting areaNanomedicineSelective targeting
2021
Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity
Martin DT, Lee JS, Liu Q, Galiana G, Sprenkle PC, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. PMID: 34740868, DOI: 10.1016/j.nano.2021.102477.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFunctionalized nanoparticlesProstate cancerTumor specificityNanoparticlesHuman prostate cancer biopsiesTumor-bearing mouse modelClaudin-3Average diameterLiver signal intensityProstate cancer biopsiesKey imaging toolContrast-enhanced MRIImaging specificityClostridium perfringens enterotoxinPotential clinical applicabilityDetection toolsMouse modelTumor localizationCancer biopsiesCancer specificityCldn-3Perfringens enterotoxinClinical applicabilityHigh expressionHigh gradeKnocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival
Liu Q, Shen H, Naguib A, Weiss RM, Martin DT. Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival. Molecular Biomedicine 2021, 2: 31. PMID: 35006480, PMCID: PMC8607359, DOI: 10.1186/s43556-021-00053-0.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProstate cancer cell growthCancer cell growthProstate cancer cellsProstate cancerLNCaP cellsCommon solid organ malignancyHuman prostate cancer specimensProstate cancer cell migrationSolid organ malignanciesAdvanced prostate cancerCancer cellsHuman prostate cancer cellsNormal human prostate cellsMetastatic human prostate cancer cellsProstate cancer specimensHuman prostate cellsCell growthNew molecular targetsCell viabilityCell migrationCancer cell migrationClaudin receptorsOrgan malignanciesProstate cancer PC3Clonogenic cell survivalThe Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRisk of BCRPI-RADS v2 scoreDefinitive local therapyBiochemical recurrencePrognostic significanceRadical prostatectomyProstate cancerV2 scoreLocal therapySystematic reviewMagnetic resonance imaging (MRI) classificationPrimary definitive treatmentIndependent prognostic significanceRisk of biasSignificant prostate cancerProstate Imaging ReportingPI-RADS v2Prostate cancer diagnosisWeb of ScienceReliable diagnostic toolOncologic outcomesDefinitive treatmentMRI findingsPI-RADSPrognostic associationGenome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancer
Liu Q, Liu G, Martin DT, Xing YT, Weiss RM, Qi J, Kang J. Genome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancer. Asian Journal Of Andrology 2021, 23: 472-478. PMID: 33762478, PMCID: PMC8451484, DOI: 10.4103/aja.aja_20_21.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDNA methylationRisk lociGene expressionGenome-wide association analysisExpression quantitative trait loci (eQTL) analysisQuantitative trait locus (QTL) analysisMethylation-regulated genesEpigenetic association studiesSingle nucleotide polymorphism analysisNucleotide polymorphism analysisTranscript regulationGenomic regionsCancer Genome AtlasEpigenetic changesEpigenetic alterationsLocus analysisAssociation studiesAssociation analysisProgression of tumorsCpG sitesGenesLociMethylationGenome AtlasImportant locusDoubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy
Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, Sprenkle PC. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.Peer-Reviewed Original ResearchAltmetricConceptsBiopsy scoreRadical prostatectomyActive surveillanceBiopsy Gleason grade groupGleason grade group 2Gleason grade group 4Low-risk prostate cancerActive surveillance populationGrade group 4Subsequent surveillance biopsiesOrgan-confined diseaseGrade group 2Gleason grade groupLow-risk categoryBiopsy reclassificationDisease reclassificationSurveillance biopsiesFinal pathologyThird biopsySecond biopsySurveillance populationProstate cancerAdverse featuresGroup 2Genomic scoreAchieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles
Li G, He S, Schätzlein AG, Weiss RM, Martin DT, Uchegbu IF. Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles. Journal Of Controlled Release 2021, 332: 210-224. PMID: 33607176, DOI: 10.1016/j.jconrel.2021.02.007.Peer-Reviewed Original ResearchCitationsAltmetric
News
News
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
- June 18, 2024
Combined Data Speak Volumes for Prostate Cancer Treatment
- May 24, 2024
The "Why" for Yale Urology Research Faculty
- April 26, 2024
Shaping Sustainable Research "Shark"-style